**11. References**


Diagnostic Evaluation of Diffuse Gliomas 217

Clark AJ.; Santos WG.; McCready J.; Chen MY.; Van Meter TE.; Ware JL.; Wolber SB.;

Colman H.; Giannini C.; Huang L.; Gonzalez J.; Hess K.; Bruner J.; Fuller G.; Langford L.;

Cosgrove M.; Fitzgibbons P.L.; Sherrod A.; Chandrasoma P.T.& Martin S.E. (1989).

Dang L.; White D.W.; Gross S.; Bennett B.D.; Bittinger M.A.; Driggers E.M.; Fantin V.R.; Jang

Deckert M.; Reifenberger G. & Wechsler W. (1989). Determination of the proliferative

Ducray F.; Mokhtari K.; Crinière E.; Idbaih A.; Marie Y.; Dehais C.; Paris S.; Carpentier C.;

Duffell D.; Farber L.; Chou S.; Hartmann J.F &; Nelson E. (1963). Electron Microscopic Observations on Astrocytomas. (1963) Am J Pathol. Vol.43, pp 539-545. Everhard S.; Kaloshi G.; Crinière E.; Benouaich-Amiel A.; Lejeune J.; Marie Y.; Sanson M.;

Franke F.E.; Schachenmayr W.; Osborn M. & Altmannsberger M. (1991). Unexpected

Fuller C.E.; Schmidt R.E.; Roth K.A.; Burger P.C.; Scheithauer B.W.; Banerjee R.; Trinkaus K.;

Gerstner L.; Jellinger K.; Heiss W.D.& Wöber G. (1977). Morphological changes in anaplastic

Giannini C.; Scheithauer B.W.; Burger P.C.; Christensen M.R.; Wollan P.C.; Sebo T.J.; Forsyth

astrocytomas. J Neuropathol Exp Neurol. Vol.58, No.1, pp 46-53.

No.3, pp 586-592.

pp 657-664.

No.2, pp 141-145.

Vol.462, No.7273, pp 739-744.

Neurol. Vol.60, No.6, pp 740-743.

1118-1128.

No.1-2, pp 117-138.

tumours. Am J Pathol Vol. 139 pp 67-79.

Res Clin Oncol. Vol.115, No.2, pp 179-188.

409 gliomas. Eur J Cancer. Vol.47, No.5, pp 802-808.

Fillmore H. & Broaddus WC. (2007). Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg. Vol.107,

Pelloski C.; Aaron J.; Burger P. & Aldape K. (2006). Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. Vol.30,No.5,

Intermediate filament expression in astrocytic neoplasms. Am J Surg Pathol. Vol.13,

H.G.; Jin S.; Keenan M.C.; Marks K.M.; Prins R.M.; Ward P.S.; Yen K.E.; Liau L.M.; Rabinowitz J.D.; Cantley L.C.; Thompson C.B.; Vander Heiden M.G. & Su SM. (2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature.

potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer

Dieme M.J.; Adam C.; Hoang-Xuan K.; Duyckaerts C.; Delattre J.Y. & Sanson M. (2011). Diagnostic and prognostic value of alpha internexin expression in a series of

Kujas M.; Mokhtari K.; Hoang-Xuan K.; Delattre J.Y. & Thillet J. (2006). MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann

immunoreactivities of intermediate filament antibodies in human brain and brain

Lytle R. & Perry A. (2003). Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol. Vol.62, No.11, pp

gliomas treated with radiation and chemotherapy. Acta Neurochir (Wien). Vol.36,

P.A.; Hayostek C.J. (1999). Cellular proliferation in pilocytic and diffuse

R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. *Acta Neuropathol*. Vol.119, No.4, pp 487-494.


http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf

Cin H.; Meyer C.; Herr R.; Janzarik W.G.; Lambert S.; Jones D.T.; Jacob K.; Benner A.; Witt H.; Remke M.; Bender S.; Falkenstein F.; Van Anh T.N.; Olbrich H.; von Deimling A.; Pekrun A.; Kulozik A.E.; Gnekow A.; Scheurlen W.; Witt O.; Omran H.; Jabado N.; Collins V.P.; Brummer T.; Marschalek R.; Lichter P.; Korshunov A. & Pfister S.M. (2011). Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. Vol. 121, No.6, pp 763-774.

Blümcke I.; Müller S.; Buslei R.; Riederer B.M & Wiestler O.D. (2004). Microtubule-

low-grade neuroepithelial tumors. *Acta Neuropathol*. Vol.108, No.2, pp 89-96. Bourne T.D. & Schiff D. (2010). Update on molecular findings, management and outcome in

Brat D.J. & Van Meir E.G. (2001). Glomeruloid microvascular proliferation orchestrated by

Brat D.J., Castellano-Sanchez A.A.; Hunter S.B.; Pecot M.; Cohen C.; Hammond E.H.; Devi

Burger P.C.; Dubois P.J; Schold S.C.; Smith K.R.; Odom G.L.; Crafts D.C. & Giangaspero F.

Burger P.C. & Scheithauer B.W. (2007). *Tumors of the Central Nervous System.; AFIP Atlas of Tumor Pathology Series 4,* ARP Press, ISBN 978-953-7619-34-3, Washington, USA Capper D.; Mittelbronn M.; Meyermann R & Schittenhelm J. (2008). Pitfalls in the

Capper D.; Weissert S.; Balss J.; Habel A.; Meyer J.; Jäger D.; Ackermann U.; Tessmer C.;

Capper D.; Reuss D.; Schittenhelm J.; Hartmann C.; Bremer J.; Sahm F.; Harter P.N.;

CBTRUS Central brain tumor registry of United States. Statistical report table (2011):

Cin H.; Meyer C.; Herr R.; Janzarik W.G.; Lambert S.; Jones D.T.; Jacob K.; Benner A.;

http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf

glioblastoma. *Acta Neuropathol*. Vol.119, No.4, pp 487-494.

low-grade gliomas. *Nat Rev Neurol*. Vol.6, No.12, pp 695-701.

population. *Cancer Res*. Vol.64, No.3, pp 920-927.

Neuropathol. Vol.115, No.2, pp 249-259.

tumors. Brain Pathol. Vol.20, No.1, pp 245-254.

789-796.

169.

241-252.

accessed:

pp 763-774.

R132 ) mutation is associated with reduced NADP+-dependent IDH activity in

associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of

VPF/VEGF: a new world of angiogenesis research. *Am J Pathol*. Vol.158, No.3, pp

S.N.; Kaur B & Van Meir E.G. (2004). Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell

(1983). Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. *J Neurosurg* Vol. 58 pp 159–

assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta

Korshunov A.; Zentgraf H.; Hartmann C. & von Deimling A. (2010). Characterization of R132H mutation-specific IDH1 antibody binding in brain

Jeibmann A.; von Deimling A. (2011). Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. Vol.121, No.2, pp

Witt H.; Remke M.; Bender S.; Falkenstein F.; Van Anh T.N.; Olbrich H.; von Deimling A.; Pekrun A.; Kulozik A.E.; Gnekow A.; Scheurlen W.; Witt O.; Omran H.; Jabado N.; Collins V.P.; Brummer T.; Marschalek R.; Lichter P.; Korshunov A. & Pfister S.M. (2011). Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. Vol. 121, No.6,


Diagnostic Evaluation of Diffuse Gliomas 219

Jeon Y.K.; Park K.; Park C.K.; Paek S.H.; Jung H.W.; Park S.H. (2007). Chromosome 1p and

Jung T.Y.; Jung S.; Moon K.S.; Kim I.Y.; Kang S.S.; Kim Y.H.; Park C.S. & Lee K.H. (2010).

Kesari S.; Schiff D.; Drappatz J.; LaFrankie D.; Doherty L.; Macklin E.A.; Muzikansky A.;

Kim Y.H.; Nobusawa S.; Mittelbronn M.; Paulus W.; Brokinkel B.; Keyvani K.; Sure U.;

Kita D.; Ciernik I.F.; Vaccarella S.; Franceschi S.; Kleihues P.; Lütolf U.M. & Ohgaki H.

Komine C.; Watanabe T.; Katayama Y.; Yoshino A.; Yokoyama T. & Fukushima T (2003).

Korshunov A.; Meyer J.; Capper D.; Christians A.; Remke M.; Witt H.; Pfister S.; von

Kösel S.; Scheithauer B.W. & Graeber M.B. (2001). Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery. Vol.48, No.1, pp 187-193. Kros J.M.; van den Brink W.A.; van Loon-van Luyt J.J. & Stefanko S.Z. (1997). Signet-ring

Kuhlmann T.; Gutenberg A.; Schulten HJ.; Paulus W.; Rohde V. & Bruck W. (2008). Nogo-a

Levin N.; Lavon I.; Zelikovitsh B.; Fuchs D.; Bokstein F.; Fellig Y. & Siegal T. (2006).

Ligon K.L.; Alberta J.A.; Kho A.T.; Weiss J.; Kwaan M.R.; Nutt CL.; Louis D.N.; Stiles C.D. &

and other gliomas? Am J Surg Pathol. Vol. 32, No.10, pp 1444-1453.

hybridization. Neuropathology. Vol.27, No.1, pp 10-20.

diffuse gliomas. Am J Pathol. Vol.177, No.6, pp 2708-2714.

Neuroepidemiology. Vol.33, No.1, pp 17-22.

Neuropathol. Vol.118, No.3, pp 401-405.

diagnosis. Acta Neuropathol. Vol.93, No.6, pp 638-643.

protein expression. Cancer. Vol. 106, No.8, pp 1759-1765.

Rep. Vol.23, No.5, pp 1269-1276.

pp 330-337.

176–184.

19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ

Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol

Santagata S.; Ligon K.L.; Norden A.D.; Ciampa A.; Bradshaw J.; Levy B.; Radakovic G.; Ramakrishna N.; Black P.M. & Wen P.Y. (2009). Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. Vol.15, No.1,

Wrede K.; Nakazato Y.; Tanaka Y.; Vital A.; Mariani L.; Stawski R.; Watanabe T.; De Girolami U.; Kleihues P. & Ohgaki H. (2010). Molecular classification of low-grade

(2009). Age as a predictive factor in glioblastomas: population-based study.

Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol Vol.13, pp

Deimling A. & Hartmann C. (2009). Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta

cell oligodendroglioma--report of two cases and discussion of the differential

expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase

Rowitch D.H. (2004). The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. Vol. 63, No.5, pp 499-509.


Giannini C.; Scheithauer B.W.; Weaver A.L.; Burger P.C.; Kros J.M.; Mork S.; Graeber M.B.;

Giannini C.; Burger P.C.; Berkey B.A.; Cairncross J.G.; Jenkins R.B.; Mehta M.; Curran W.J. &

Hartmann C.; Meyer J.; Balss J.; Capper D.; Mueller W.; Christians A.; Felsberg J.; Wolter M.;

Hartmann C.; Hentschel B.; Wick W.; Capper D.; Felsberg J.; Simon M.; Westphal M.;

classification of gliomas. Acta Neuropathol. Vol.120, No.6, pp 707-718. Hashiba T.; Izumoto S.; Kagawa N.; Suzuki T.; Hashimoto N.; Maruno M. & Yoshimine T.

Hasselblatt M. & Paulus W. (2003). Sensitivity and specificity of epithelial membrane

Hegi M.E.; Diserens A.C.; Gorlia T.; Hamou M.F.; de Tribolet N.; Weller M.; Kros J.M.;

Hussein M.R.; El-Ghorori R.M. & El-Rahman Y.G. (2006). Alterations of p53, BCL-2 and

Jaiswal S.; Agrawal V.; Vij M.; Sahu R.N.; Jaiswal A.K. & Behari S. (2010) Glioblastoma with melanotic differentiation. Clin Neuropathol. Vol. 29, No.5, pp 330-333. Jaros E.; Perry R.H.; Adam L.; Kelly P.J.; Crawford P.J.; Kalbag R.M.; Mendelow A.D.;

tumors. Neurol Med Chir (Tokyo). Vol.47, No.4, pp 165-170.

Neuropathology. Vol.30, No.6, pp 586-596.

Exp Pathol. Vol.87, No.4, pp 297-306.

Cancer. Vol.66, No.2, pp 373-385.

Neuropathol Exp Neurol. Vol.60, No.3, pp 248-262.

369.

385-388.

Vol.118,No.4, pp 469-474.

Bauserman S.; Buckner J.C.; Burton J.; Riepe R.; Tazelaar H.D.; Nascimento A.G.; Crotty T.; Keeney G.L.; Pernicone P. & Altermatt H. (2001). Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J

Aldape K. (2008). Anaplastic oligodendroglial tumors: refining the correlation among histopathology: 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. Vol.18, No.3, pp 360-

Mawrin C.; Wick W.; Weller M.; Herold-Mende C.; Unterberg A.; Jeuken J.W.; Wesseling P.; Reifenberger G.; von Deimling A. (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1.010 diffuse gliomas. Acta Neuropathol.

Schackert G.; Meyermann R.; Pietsch T.; Reifenberger G.; Weller M.; Loeffler M. & von Deimling A. (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for

(2007). Expression of WT1 protein and correlation with cellular proliferation in glial

antigen staining patterns in ependymomas. Acta Neuropathol. Vol.106, No.4, pp

Hainfellner J.A.; Mason W.; Mariani L.; Bromberg J.E.; Hau P.; Mirimanoff R.O.; Cairncross J.G.; Janzer R.C.& Stupp R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. Vol.352, No.10, pp 997-1003. Hirose T.; Ishizawa K. & Shimada S. (2010). Utility of in situ demonstration of 1p loss and

p53 overexpression in pathologic diagnosis of oligodendroglial tumors.

hMSH2 protein expression in the normal brain tissues, gliosis and gliomas. Int J

Sengupta R.P. & Pearson AD. (1992). Prognostic implications of p53 protein.; epidermal growth factor receptor.; and Ki-67 labelling in brain tumours. Br J


Diagnostic Evaluation of Diffuse Gliomas 221

Peraud A.; Kreth F.W.; Wiestler O.D.; Kleihues P. & Reulen H.J. (2002). Prognostic impact of

Prayson R.A. & Estes M.L. (1996). MIB1 and p53 immunoreactivity in protoplasmic

Preusser M.; Janzer C.R.; Felsberg J.; Reifenberger G.; Hamou M.F.; Diserens A.C.; Stupp R.;

impede its use as clinical biomarker. Brain Pathol. Vol.18, No.4, pp 520-532. Preusser M.; Elezi L. & Hainfellner J.A. (2008). Reliability and reproducibility of PCR-based

Riemenschneider M.J.; Jeuken J.W.; Wesseling P & Reifenberger G. (2010). Molecular

Rodriguez F.J.; Scheithauer B.W.; Giannini C.; Bryant S.C. & Jenkins R.B. (2008). Epithelial

Rushing E.J.; Sandberg G.D. & Horkayne-Szakaly I. (2010). High-grade astrocytomas show

Sallinen P.K.; Haapasalo H.K.; Visakorpi T.; Helén P.T.; Rantala I.S.; Isola J.J. & Helin H.J.

Sanson M.; Marie Y.; Paris S.; Idbaih A.; Laffaire J.; Ducray F.; El Hallani S.; Boisselier B.;

Scherer HJ. (1983). Structural development in gliomas. Am J Cancer 1938; 34: 333–351. Schindler G.; Capper D.; Meyer J.; Janzarik W.; Omran H.; Herold-Mende C.; Schmieder

astrocytomas. Pathol Int. Vol.46, No.11, pp 862-866.

specimens. Clin Neuropathol. Vol.27, No.6, pp 388-390.

Vol.58, No.4, pp 313-320.

567-584.

2779-2789.

No.4, pp 275-282.

397-405.

Pathol. Vol.18, No.4, pp 255-259.

Vol.27, No.25, pp 4150-4154.

TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res. Vol.8, No.5, pp 1117-1124. Plate KH. (1999). Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol.

Gorlia T.; Marosi C.; Heinzl H.; Hainfellner J.A. & Hegi M. (2008). Anti-O6 methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival

testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy

diagnostics of gliomas: state of the art. Acta Neuropathol. 2010 Vol.120, No.5, pp

and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. Vol.113, No.10, pp

increased Nestin and Wilms's tumor gene No.WT1) protein expression. Int J Surg

(1994). Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol. Vol.174,

Mokhtari K.; Hoang-Xuan K. & Delattre J.Y. (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol.

K.; Wesseling P.; Mawrin C.; Hasselblatt M.; Louis D.N.; Korshunov A.; Pfister S.; Hartmann C.; Paulus W.; Reifenberger G. & von Deimling A. (2011). Analysis of BRAF V600E mutation in 1.;320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. Vol.121, No.3, pp


Louis DN.; Ohgaki H.; Wiestler OD. & Cavenee WK. WHO Classification of Tumours of The

Louis D.N.; Ohgaki H.; Wiestler O.D.; Cavenee W.K.; Burger P.C.; Jouvet A.; Scheithauer

McLendon R.E.; Herndon J.E 2nd.; West B.; Reardon D.; Wiltshire R.; Rasheed B.K.; Quinn J.;

Meis J.M.; Martz K.L. & Nelson J.S. (1991). Mixed glioblastoma multiforme and sarcoma. A

Meyer J.; Pusch S.; Balss J.; Capper D.; Mueller W.; Christians A.; Hartmann C. & von

Min K.W. & Scheithauer BW. (1994). Oligodendroglioma: the ultrastructural spectrum.

Mittelbronn M.; Wolff M.; Bültmann E.; Nägele T.; Capper D.; Beck R.; Meyermann R. &

Ng H.K. & Lo S.T.H. (1989). Cytokeratin immunoreactivity in gliomas. Histopathol 1989;

Nobusawa S.; Watanabe T.; Kleihues P. & Ohgaki H. (2009). IDH1 mutations as molecular

Ohgaki H & Kleihues P. (2005). Population-based studies on incidence, survival rates and

Ohgaki H & Kleihues P. (2005). Epidemiology and etiology of gliomas. Acta Neuropathol.

Ohgaki H & Kleihues P. (2007). Genetic pathways to primary and secondary glioblastoma.

Okamoto Y.; Di Patre P.L.; Burkhard C.; Horstmann S.; Jourde B.; Fahey M.; Schüler D.;

Palma L.; Celli P.; Maleci A.; Di Lorenzo N. & Cantore G. (1989). Malignant monstrocellular

Nervous System. Acta Neuropathol. Vol.114, No.2, pp 97–109.

B.W & Kleihues P. (2007). The 2007 WHO Classification of Tumours of the Central

Friedman H.S.; Friedman A.H.; Bigner D.D. (2005) Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. Vol.104, No.8, pp 1693-

clinicopathologic study of 26 radiation therapy oncology group cases. Cancer.

Deimling A. (2010). PCR- and restriction endonuclease-based detection of IDH1

Beschorner R. (2005). Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-

signature and predictive factor of secondary glioblastomas. Clin Cancer Res. Vol.15,

genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp

Probst-Hensch N.M.; Yasargil M.G.; Yonekawa Y.; Lütolf U.M.; Kleihues P. & Ohgaki H. (2004). Population-based study on incidence.; survival rates.; and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta

brain tumours. A study of 42 surgically treated cases. Acta Neurochir (Wien).

Central Nervous system IARC Press Lyon 2007

mutations. Brain Pathol. Vol.20, No.2, pp 298-300.

year-old boy. Hum Pathol. Vol.36, No.7, pp 854-857.

Ultrastruct Pathol. Vol.18, No.1-2, pp 47-56.

1699.

Vol.67, No.9, pp 2342-2349.

Vol. 14, pp 359-368.

No.19, pp 6002-6007.

Vol.109, No.1, pp 93-108.

Vol.97, No.1-2, pp 17-25.

Neurol. Vol.64, No.6, pp 479-489.

Am J Pathol. Vol.170, No.5, pp 1445-1453.

Neuropathol. Vol.108, No.1, pp 49-56.


Diagnostic Evaluation of Diffuse Gliomas 223

Wick W.; Hartmann C.; Engel C.; Stoffels M.; Felsberg J.; Stockhammer F Sabel MC,

van den Bent MJ.; Dubbink H.J.; Sanson M.; van der Lee-Haarloo C.R.; Hegi M.; Jeuken J.W.;

van den Bent M.J.; Carpentier A.F.; Brandes A.A.; Sanson M.; Taphoorn M.J.; Bernsen H.J.;

von Deimling A.; Korshunov A. & Hartmann C. (2011). The next generation of glioma

Vital A.; Loiseau H.; Kantor G.; Daucourt V.; Chene G.; Cohadon F.; Rougier A.; Rivel J. &

Watanabe K.; Sato K.; Biernat W.; Tachibana O.; von Ammon K.; Ogata N.; Yonekawa Y.;

Watanabe K.; Peraud A.; Gratas C.; Wakai S.; Kleihues P. & Ohgaki H. (1998). p53 and PTEN

Weller M.; Felsberg J.; Hartmann C.; Berger H.; Steinbach J.P.; Schramm J.; Westphal M.;

Yan H.; Parsons DW.; Jin G.; McLendon R.; Rasheed BA.; Yuan W.; Kos I.; Batinic-Haberle I.;

mutations in gliomas. N Engl J Med. Vol.360, No.8, pp 765-773.

Network. J Clin Oncol. Vol.27, No.34, pp 5743-5750.

Clin Oncol. Vol.27, pp 5874–5880.

Clin Oncol. Vol.27, No.35, pp 5881-5886.

2715-2722.

2011 Vol.21, No.1, pp 74-87.

No.4, pp 523-530.

559-564.

Pract. Vol.194, No.12, pp 831-836.

Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R.D, Pietsch T, Wiestler O.D, Ernemann U, Bamberg M, Reifenberger G, von Deimling A & Weller M. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine and vincristine or temozolomide. J

Ibdaih A.; Brandes A.A.; Taphoorn M.J.; Frenay M.; Lacombe D.; Gorlia T.; Dinjens W.N. & Kros J.M. (2009). MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J

Frenay M.; Tijssen C.C.; Grisold W.; Sipos L.; Haaxma-Reiche H.; Kros J.M.; van Kouwenhoven M.C.; Vecht C.J.; Allgeier A.; Lacombe D. & Gorlia T. (2006). Adjuvant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. Vol.24, No.18, pp

biomarkers: MGMT methylation.; BRAF fusions and IDH1 mutations. Brain Pathol.

Vital C. (1998). p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res

Kleihues P. & Ohgaki H. (1997). Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. Vol.3,

gene mutations in gemistocytic astrocytomas. Acta Neuropathol. Vol.95, No.6, pp

Schackert G.; Simon M.; Tonn JC.; Heese O.; Krex D.; Nikkhah G.; Pietsch T.; Wiestler O.; Reifenberger G.; von Deimling A. & Loeffler M. (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma

Jones S.; Riggins GJ.; Friedman H.; Friedman A.; Reardon D.; Herndon J.; Kinzler K.W.; Velculescu V.E.; Vogelstein B & Bigner D.D. (2009). IDH1 and IDH2


Schittenhelm J.; Erdmann T.; Maennlin S.; Will B.E.; Beschorner R.; Bornemann A.;

Schittenhelm J.; Beschorner R.; Simon P.; Tabatabai G.; Herrmann C.; Schlaszus H.;

Schittenhelm J. & Psaras T. (2010). Glioblastoma with granular cell astrocytoma features: a case report and literature review. Clin Neuropathol. Vol.29, No.5, pp 323-329. Simmons M.L.; Lamborn K.R.; Takahashi M.; Chen P.; Israel M.A.; Berger M.S.; Godfrey T.;

Ständer M.; Peraud A.; Leroch B. & Kreth FW. (2004). Prognostic impact of TP53 mutation

Stavrinou P.; Magras I.; Stavrinou L.C.; Zaraboukas T.; Polyzoidis K.S. & Selviaridis P.

Tabatabai G.; Stupp R.; van den Bent M.J.; Hegi M.E.; Tonn J.C.; Wick W. & Weller M.

Tabuchi K.; Moriya Y.; Furuta T.; Ohnishi R & Nishimoto A. (1982). S-100 protein in human

Takeuchi J. & Barnard R.O. (1976). Perivascular lymphocytic cuffing in astrocytomas. Acta

Tascos N.A.; Parr J. & Gonatas N.K. (1982). Immunocytochemical study of the glial fibrillary

Tihan T.; Vohra P.; Berger M.S. & Keles G.E. (2006). Definition and diagnostic implications

Waidelich J.; Schittenhelm J.; Allmendinger O.; Meyermann R & Beschorner R (2010).

Wharton SB.; Chan KK. & Whittle I.R. (2002). Microtubule-associated protein 2 (MAP-2) is

survival in glioblastoma patients. Cancer Res. Vol. 61, pp 1122–1128. Srivastava A.; Jain A.; Jha P.; Suri V.; Sharma M.C.; Mallick S.; Puri T.; Gupta D.K.; Gupta A.;

differentiation. Neuropathology. Vol.27, No.1, pp 90-94.

Childs Nerv Syst. Vol.26, No.11, pp 1613-1618.

analysis. Cen Eur Neurosurg. Vol.71, No.1, pp 46-49.

Neuropathol. Vol.120, No.5, pp 585-592.

Neuropathol. Vol.35, No.3, pp 265-271.

69-81.

1028-1035.

No.3-4, pp 239-251.

No.2, pp 175-183.

(Suppl. 1), pp 1–99.

pp 165-169.

1982 May;13No.5, pp 454-8.

Meyermann R. & Mittelbronn M. (2007). Gliosarcoma with chondroid and osseous

Capper D.; Weller M.; Meyermann R.; Mittelbronn M. (2009). Diagnostic value of WT1 in neuroepithelial tumours. Neuropathol Appl Neurobiol. Vol.35, No.1, pp

Nigro J.; Prados M.; Chang S-; Barker F.G. 2nd & Aldape K. (2001). Analysis of complex relationships between age, p53, epidermal growth factor receptor, and

Sarkar C. (2010). MGMT gene promoter methylation in pediatric glioblastomas.

status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer. Vol.101, No.5, pp

(2010). Primary extracerebral meningeal glioblastoma: clinical and pathological

(2010). Molecular diagnostics of gliomas: the clinical perspective. Acta

glial tumours. Qualitative and quantitative studies. Acta Neurochir (Wien). Vol.65,

acidic protein in human neoplasms of the central nervous system. Hum Pathol.

of gemistocytic astrocytomas: a pathological perspective. J Neurooncol. Vol.76,

Glutamate transporters in diagnostic neurooncology. Brain Pathology Vol. 20,

expressed in low and high grade diffuse astrocytomas. J Clin Neurosci. Vol.9, No.2,


Brain cancer is a life threatening neurological disorder in which malignant cells, grow, proliferate and invade the original cerebral structures of the host, hampering seriously adequate brain function. Malignant cells generate eventually a dedifferentiated tumoral mass that interferes with vital brain functions as sensory and motor activations, memory and perception and neuroendocrine regulation, among others. The fully developed tumoral mass consumes a significant part of cerebral volume resulting in cerebral compression and serious neurological impairments, such as vision or hearing disturbances and eventually lethal cerebrovascular complications. Most brain tumors remain asymptomatic during early development, revealing their symptoms and lethal nature only at later stages. Therapy is facilitated many times by an early finding, a circumstance making the neuroimaging

In the last decades, Magnetic Resonance Imaging (MRI) approaches have evolved into the most powerful and versatile imaging tool for brain tumor diagnosis, prognosis, therapy evaluation, monitoring of disease progression and planning of neurosurgical strategies. MRI methods enable the non invasive assessment of glioma morphology and functionality providing a point of likeness into histopathological grading of the tumor and helping in this way a more successful patient management. This impressive evolution is based not only for the high resolution and quality of the anatomical images obtained, but on the additional possibilities to achieve quantitative functional information on tumoral physiopathology and its repercussions in the sensorial, motor and integrative functions through the brain. The use of conventional paramagnetic or superparamagnetic contrast media allows for the identification of areas with blood-brain barrier (BBB) disruption and the recent molecular imaging approaches enable researchers to visualize molecular events associated to tumor proliferation and invasion, bringing the potentials of diagnostic imaging to the cellular and molecular aspects of tumor biology. Moreover, functional MRI approaches as performed in the clinic are endowed with the potential to detect and characterize the earliest

approaches particularly useful in the detection and handling of these lesions.

neoangiogenic, metabolic and hemodynamic alterations induced by the neoplasm.

Several advanced magnetic resonance (MR) methodologies have been proposed in the last years to assess the functional competence in healthy and pathologic brain tissue. Diffusion and perfusion MRI are probably the two main approaches that have reached a relevant clinical role

**1. Introduction** 

Pilar López-Larrubia, Eva Cañadillas-Cárdenas,

Aire Salguero and Sebastián Cerdán

*Spain* 

Ana M. Metelo, Nuria Arias, Miguel Martínez-Maestro,

*Instituto de Investigaciones Biomédicas "Alberto Sols", CSIC-UAM* 

Yung WK.; Luna M. & Borit A (1985). Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol. Vol.3, No.1, pp 35-38. **12** 

Pilar López-Larrubia, Eva Cañadillas-Cárdenas, Ana M. Metelo, Nuria Arias, Miguel Martínez-Maestro, Aire Salguero and Sebastián Cerdán *Instituto de Investigaciones Biomédicas "Alberto Sols", CSIC-UAM Spain* 
